Geroprotectors

The "longevity molecule" category — pharmacological and nutraceutical agents proposed to target the hallmarks of aging directly. The honest assessment of the field as of 2026: mechanistic promise is rich, human translation is thin, and industry funding distorts the published literature significantly.

The class as a whole

Two truths often missing from longevity content:

1. No supplement on the market has been shown to extend life in healthy adults at the magnitude of basic lifestyle interventions. No "longevity molecule" comes close to the effect of regular exercise, Mediterranean-pattern eating, or quitting smoking.

2. The gap between mechanistic promise and clinical translation is widening, not narrowing, for the entire emerging-longevity category. Five years of further research has, on net, deflated rather than confirmed most claims.

That said, this is an active and evolving field. Some agents (rapamycin, SGLT2 inhibitors) have stronger biological signals than others (resveratrol, NMN at typical OTC doses).

Tier 1: Best human evidence among geroprotectors

Rapamycin (and rapalogs) — Moderate (mechanistic / surrogate); Weak (hard outcomes)

The closest thing to a true gerotherapeutic in 2026.

The case for:

• mTOR inhibition extends lifespan in mice 10–25%, replicated multiple times.
• Improves immune response to vaccination in older adults.^[1]
• Multiple ongoing trials testing low-dose intermittent rapamycin in healthy adults.^[2]
• Mechanistic: directly inhibits mTOR, the most heavily targeted antagonistic hallmark.

The case for caution:

• No human RCT with hard longevity outcomes.
• Side effects: mouth ulcers, lipid abnormalities, glucose dysregulation, immunosuppression.
• Dosing is far from optimized for healthy-adult use.
• Not approved for longevity indication; off-label use is increasing but unmonitored.

Practical: Some clinicians prescribe low-dose intermittent rapamycin (5–6 mg weekly) off-label. Without longer human safety data this remains experimental — appropriate only in informed adults working with a knowledgeable physician.

Metformin — Moderate

A widely studied biguanide originally for T2D.

The case for:

• AMPK activator (the catabolic counterweight to mTOR).
• Multiple cohorts (UKPDS extension, CPRD database) showed lower all-cause mortality in T2D patients on metformin vs. sulfonylureas — possibly even compared to non-diabetic populations.
• The TAME (Targeting Aging with Metformin) trial is the first major attempt to evaluate aging biomarkers in non-diabetic adults; results pending.

The case for caution:

• Some evidence of blunted exercise adaptations (Konopka 2018) — concerning for active adults relying on training for longevity.
• Vitamin B12 deficiency risk with chronic use.
• Modest GI side effects.
• No approved indication for healthy non-diabetic use.

Practical: For healthy adults, the cost-benefit currently favors not using metformin off-label. The exercise interaction is concerning. For prediabetics or T2D, it's the established first-line drug.

SGLT2 inhibitors (empagliflozin, dapagliflozin) — Strong (in disease populations)

A newer class with surprising longevity-relevant signals.

The case for:

• Reduce all-cause mortality in T2D, heart failure, and CKD populations (EMPA-REG, DAPA-HF, EMPEROR trials).
• Pleiotropic effects beyond glucose: reduced cardiac remodeling, reduced renal decline, improved autophagy markers.
• Hypothesized as longevity drugs in healthy adults; early trials beginning.

The case for caution:

• Approved only for T2D, HF, and CKD.
• Side effects: increased UTI/genital mycotic infections, rare diabetic ketoacidosis.
• No safety/efficacy data in healthy adults.

Practical: For longevity-only off-label use in healthy adults, the evidence is currently insufficient to recommend.

GLP-1 receptor agonists (semaglutide, tirzepatide) — Moderate (and growing)

The newest, most contested entry in Tier 1. The first drug class with measurable deceleration of validated epigenetic aging clocks in a randomized human trial (GrimAgeV2 −2.26 years over 32 weeks), on top of a 20% reduction in major cardiovascular events (SELECT) and durable double-digit weight loss in non-diabetic adults. The same biology that drives those benefits also drives meaningful muscle and bone loss unless the patient eats enough protein and trains. Off-label "microdosing" for healthy adults is plausible but unproven and carries real compounding-pharmacy risks.

Practical: For an adult with overweight/obesity and cardiometabolic risk, the evidence is now strong enough to consider seriously. For a healthy normal-BMI adult chasing longevity alone, the case is interesting but not yet made — and never start without protein and resistance training in place.

→ Full treatment in GLP-1 receptor agonists: Ozempic, Wegovy, and the longevity question.

Tier 2: Mechanistically interesting, weak human evidence

NAD+ precursors: NMN and NR

Both reliably elevate blood NAD+ at 250–1000 mg/day. Whether this translates to clinical benefit in healthy adults is essentially unproven.

• Muscle insulin sensitivity gains in postmenopausal prediabetic women with NMN 250 mg.^[3]
• Small SBP reduction with NR 1000 mg in stage-1 hypertensives.^[4]
• NR 2000 mg in obese men — completely negative for insulin sensitivity, mitochondrial function, body composition.^[5]

A new concern: NR may raise 2-PY and 4-PY metabolites, recently linked to cardiovascular events in observational data.^[6] Biological significance unclear.

Regulatory note: NMN's status flipped multiple times — FDA excluded it as a supplement in 2022, then reversed in 2025. NR (Niagen) has been on stable footing throughout.

Practical: The hype substantially outruns the evidence. Save the money.

Urolithin A (Mitopure)

Best industry-funded RCT data of any novel compound. The ATLAS trial (n=88 overweight middle-aged adults) found ~12% leg-strength gain, +10% peak VO2, reduced inflammatory markers — but primary endpoint (peak power) was missed.^[7]00097-X)

• Only 30–40% of people convert dietary ellagitannins (pomegranate, walnuts) to urolithin A endogenously.
• All trials are sponsor-run (Amazentis); no hard outcomes studied.

Practical: A defensible niche option for older adults with sarcopenia who don't endogenously convert. For most, eating pomegranate and walnuts is the cheaper bet.

Spermidine

Rich animal data and a striking observational signal — the Bruneck cohort showed highest tertile dietary intake had 39% lower all-cause mortality.^[8]

But the SmartAge RCT (n=100) was negative on its primary cognitive endpoint.^[9]

Practical: Dietary intake from Mediterranean-style eating (legumes, mushrooms, aged cheese, wheat germ, natto) is preferable to wheat germ extract pills.

Quercetin

500–1000 mg/day shows modest BP-lowering (~2–3 mmHg SBP). Phytosomal forms (Quercefit) better absorbed.

The senolytic dasatinib + quercetin protocol from the Mayo Clinic Kirkland group has reduced senescent-cell markers in human pilots, but dasatinib is a prescription leukemia drug — this is not a self-administration regimen.

Caution: Quercetin is a CYP3A4 inhibitor with real interactions (statins, cyclosporine, warfarin).

Tier 3: Hyped but weak human evidence

Resveratrol

The cautionary tale of the field. Extreme bioavailability problems (<1% oral), two decades of human trials, disappointingly inconsistent results.

• RESHAW (postmenopausal women, 150 mg/day) is the most positive trial — single-site, industry-funded.^[10]
• Yoshino 2012,^[11] Poulsen 2013,^[12] and others are largely null.

Red wine contains too little resveratrol to matter (~0.3–1 mg per glass). Whole-food polyphenol diversity beats isolated resveratrol as a defensible recommendation.

Taurine

Got Science cover treatment with a 12% mouse lifespan extension claim.^[13] But a 2024 Science paper directly contradicted the central claim, showing circulating taurine does not consistently decline with age in humans or monkeys.^[14]

Practical: Currently speculative. No RCT in healthy 35–55-year-olds targeting longevity.

GlyNAC (glycine + N-acetylcysteine)

Comes entirely from the Sekhar lab at Baylor — small pilot trials showing improvements in glutathione, mitochondrial function, and aging biomarkers in older adults at 100 mg/kg/day of each.

Independent replication is absent, and trial sizes are small.

NAC alone (600–1800 mg/day) has solid evidence for COPD exacerbation reduction and is the standard antidote for acetaminophen overdose. Glycine alone (3 g pre-bed) has small Japanese trials suggesting modest sleep benefit.

Berberine

500 mg, 2–3× daily has strong short-term evidence for glucose and lipid lowering — comparable to metformin in head-to-head trials, with LDL-C reductions of ~15 mg/dL via PCSK9 modulation.

But berberine has no diabetes-prevention RCTs, no cardiovascular outcome trials, and no proven longevity equivalence to metformin despite being marketed as "natural metformin."

Caution: Potent CYP3A4 and P-gp inhibitor with real interactions affecting statins, cyclosporine, dabigatran, and many BP medications. GI side effects in 10–35% of users.

Low-dose lithium orotate

Only ecological/observational evidence — drinking-water lithium associates inversely with suicide and dementia rates across multiple meta-analyses.

A landmark 2025 Nature paper showed endogenous brain lithium is depleted in MCI/AD and that low-dose lithium orotate reversed pathology in mice.^[15] No RCT of microdose lithium orotate exists in healthy adults.

The supplement is safe at these doses but the longevity evidence is purely hypothesis-generating.

What to actually do

For a healthy 35–55-year-old, the realistic options are:

1. Skip the geroprotector category entirely — focus on sleep, exercise, diet, and the core supplement stack. Captures 95%+ of available benefit at much lower cost and risk.

2. For those willing to experiment — a minimal "biology-aware" approach:

   • Optional creatine (already in the core stack)
   • Optional spermidine via diet (legumes, mushrooms, aged cheese)
   • Optional polyphenol-rich diet (berries, EVOO, dark chocolate, tea)
   • These are food, not supplements

3. For those drawn to pharmacological geroprotectors — work with a clinician knowledgeable in this area, not a marketing site. Rapamycin and SGLT2 inhibitors are the only agents currently with substantive biological signal, and both have meaningful side effects.

The "longevity stack" sold online — NMN, resveratrol, urolithin A, spermidine, lithium orotate, plus 10 other compounds — is currently unsupported by human RCT evidence and represents the worst kind of cocktail-of-everything approach.

Further reading

• López-Otín C et al. Hallmarks of aging: An expanding universe. Cell 2023.^[16]
• Mannick JB et al. TORC1 inhibition enhances immune function in the elderly. Sci Transl Med 2018.^[17]
• Ferrell M et al. A terminal metabolite of niacin promotes vascular inflammation. Nat Med 2024.^[18]
• Singh A et al. Urolithin A: ATLAS trial. Cell Reports Medicine 2022.^[19]00097-X)
• Schwarz C et al. SmartAge: Spermidine and Cognition. JAMA Network Open 2022.^[20]
• Yoshino M et al. NMN improves muscle insulin sensitivity in postmenopausal prediabetic women. Science 2021.^[21]
• Aron L et al. Lithium and Alzheimer's pathology. Nature 2025.^[22]
• Rapamycin for longevity: pros, cons, and future perspectives. Front Aging 2025.^[23]
• Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging 2023.^[24]

---